牦牛LIFR 基因的克隆及其在繁殖周期卵巢中的表达

白血病抑制因子受体(LIFR)与白血病抑制因子(LIF)结合,在排卵、胚胎发育及胚胎附植等过程中起重要的调节作用,与哺乳动物生殖过程密切相关。为进一步研究白血病抑制因子受体(LIFR)基因在卵巢中的表达,本研究对牦牛LIFR 基因进行克隆和序列分析,并利用RT-PCR 技术研究其在繁殖周期卵巢中的表达情况。本研究克隆得到牦牛3 329 bp 的LIFR 基因cDNA 序列,内含3 288 bp 开放阅读框序列。与家牛的相应序列具有很高的同源性(99 5% ),表明LIFR 基因在进化过程中较为保守。实时定量RT-PCR 检测LIFR 基因在繁殖周期卵巢中的表达,结果显示卵巢中LIFR 基因在妊娠期表达最强。表明LIFR 基因在牦牛繁殖周期中具有不可忽视的作用。     

Ikaros通过靶向调控 c-KIT抑制B-ALL白血病细胞的增殖

Ikaros是一种重要的造血细胞分化与发育调控因子，其基因结构、蛋白质活性的改变与淋巴细胞白血病的发生密切相关。致癌基因c-KIT与白血病的发生有直接联系，但Ikaros与c-KIT之间的调控关系尚未见报道。本研究报道，在人急性B淋巴细胞白血病（B-acute lymphoblastic leukemia, B-ALL）细胞中，Ikaros可靶向调控c KIT基因的转录与蛋白质表达。通过在人B ALL细胞系Nalm6中分别高表达和shRNA干扰Ikaros后，qRT-PCR与 Western 印迹结果显示，Ikaros可直接抑制c-KIT基因的表达。双荧光素酶报告实验检测Ikaros及其突变体对c-KIT基因的直接靶向作用。结果显示，野生型Ikaros可明显抑制c-KIT的表达，而突变体则不能。进一步利用染色质免疫共沉淀技术（chromatin immunoprecipitation，ChIP），检测Ikaros对c-KIT上游启动子序列的结合活力。结果显示，Ikaros蛋白在c KIT的上游调控区约-500 bp处有明显的结合。Ikaros通过靶向c-KIT上游启动子，抑制c-KIT表达，抑制B-ALL细胞的增殖，为临床治疗白血病提供了新思路。     

Ikaros通过靶向c-KIT抑制B-ALL白血病细胞的增殖

Ikaros是一种重要的造血细胞分化与发育调控因子,其基因结构、蛋白质活性的改变与淋巴细胞白血病的发生密切相关。致癌基因c-KIT与白血病的发生有直接联系,但Ikaros与c-KIT之间的调控关系尚未见报道。本研究报道,在人急性B淋巴细胞白血病(B-acute lymphoblastic leukemia,B-ALL)细胞中,Ikaros可靶向调控c-KIT基因的转录与蛋白质表达。通过在人B-ALL细胞系Nalm6中分别高表达和shRNA干扰Ikaros后,qRT-PCR与Western印迹结果显示,Ikaros可直接抑制c-KIT基因的表达。双荧光素酶报告实验检测Ikaros及其突变体对c-KIT基因的直接靶向作用。结果显示,野生型Ikaros可明显抑制c-KIT的表达,而突变体则不能。进一步利用染色质免疫共沉淀技术(chromatin-immunoprecipitation,Ch IP),检测Ikaros对c-KIT上游启动子序列的结合活力。结果显示,Ikaros蛋白在c-KIT的上游调控区约-500 bp处有明显的结合。Ikaros通过靶向cKIT上游启动子,抑制c-KIT表达,抑制B-ALL细胞的增殖,为临床治疗白血病提供了新思路。     

Aptamer-siRNA核酸复合物对人慢性粒细胞白血病(CML)小鼠模型凋亡信号转导的影响

SELEX技术筛选人慢性粒细胞白血病(CML)核酸适配子,合成aptamer-si RNA核酸复合物,观察aptamer-si RNA核酸复合物干预NOD/SCID小鼠慢性粒细胞白血病(CML)bcr-abl融合基因及P210、P53、TNF-α、bcl-xl相关因子表达水平。将K562细胞接种于全身照射后的裸鼠,待皮下成瘤后取出瘤块,制备成瘤细胞混悬液,再尾静脉接种于NOD/SCID小鼠,实验成功建立了全身播散型白血病模型,对实验小鼠行随机分组,以RT-PCR法检测aptamer-si RNA核酸复合物治疗小鼠体内bcr-abl融合基因表达水平,ELASA法检测小鼠P210、P53、TNF-α、bcl-xl表达水平。实验结果表明:Aptamer-si RNA核酸复合物可显著降低模型小鼠体内融合基因bcr-abl及融合蛋白P210表达水平,能提升P53表达,抑制TNF-α、bcl-xl过度表达,其抑制效果与aptamer-si RNA核酸复合物浓度有一定的相关性。aptamer-si RNA核酸复合物通过干预CMLbcr-abl融合基因及其表达的融合蛋白P210,影响细胞信号传导通路途径,有效阻断了CML传变的进展,揭示了aptamer-si RNA核酸复合物干预CML疾病的微观机理。     

禽白血病病毒p19基因末端片段在大肠杆菌中的表达

根据禽白血病病毒（ALV）p19基因末端序列合成一条82 bp的双链DNA片段,将其克隆到表达质粒pGEMEX-1中,序列分析结果与设计的相符。重组表达质粒转化的大肠杆菌BL21（DE3）经IPTG诱导后产生34kD融合表达产物,与理论值相符;Western-blot分析表明该表达产物能与兔抗ALV血清发生反应。     

一种高效抑制Jurkat细胞表达RhoGDI2的方法

目的:RhoGDI2是RhoGTP酶的解离抑制因子,在白血病细胞内表达量很高。构建Rho GDI2短发夹RNA(sh RNA)的慢病毒载体,并鉴定该慢病毒在急性T细胞白血病细胞系Jurkat内的抑制效率。方法:针对人rho GDI2基因序列合成sh RNA序列,通过限制性内切酶Bam HⅠ和XhoⅠ、T4DNA连接酶,将该sh RNA序列插入慢病毒载体p EN_h H1c,测序正确后通过LR重组酶与p DSL_hp UGIP重组,转化感受态细菌,筛选阳性克隆,测序鉴定正确后用脂质体法将质粒与ps PAX2、p MD2共转染293T细胞、包装病毒并侵染Jurkat细胞,采用荧光显微镜观察侵染效率、West-ern印迹鉴定Rho GDI2 sh RNA在Jurkat细胞内的表达。结果:构建的Rho GDI2 sh RNA慢病毒成功侵染Jurkat细胞并抑制Rho GDI2的表达。结论:构建并鉴定了RhoGDI2 shRNA的慢病毒表达质粒,为研究RhoGDI2在白血病中的作用奠定了基础。     

凋亡抑制因子Survivin在大肠杆菌TB1中的表达纯化及鉴定

 本文旨在克隆凋亡抑制因子Survivin基因,并在大肠杆菌中进行可溶性表达与初步纯化. 采用RT-PCR法,扩增人凋亡抑制因子survivin cDNA,并克隆入原核表达载体pMAL p2X中,转化TB1大肠杆菌感受态细胞.经0.3 mmol/L IPTG诱导2 h后,收集菌体蛋白,进行SDS-PAGE、ELISA及Western 印迹鉴定. 实验获得凋亡抑制因子survivin编码区cDNA,以构建的原核表达载体pMAL-p2X survivin转化菌株后,可表达凋亡抑制因子survivin和麦芽糖结合蛋白(MBP)的融合蛋白,相对分子质量(Mr) 为58 000.并成功利用Factor Xa将融合蛋白裂解开.ELISA和Western 印迹表明,融合蛋白能与抗凋亡抑制因子survivin单克隆抗体特异性结合.获得的凋亡抑制因子survivin全长cDNA可在大肠杆菌TB1中以MBP survivin融合蛋白的形式表达,成功地将survivin目的蛋白和MBP蛋白分离,为深入研究survivin的结构和功能奠定了基础.     

禽白血病病毒p19基因末端片段在大肠杆菌中的表达

根据禽白血病病毒（ALV）p19基因末端序列合成一条82bp的双链DNA片段,将其克隆到表达质粒pGE-MEX-1中,序列分析结果与设计的相符。重组表达质粒转化的大肠杆菌BL21（ＤＥ３）经ＩＰＴＧ诱导后产生３４kD融合表达产物,与理论值相符;Western-blot分析表明该表达产物能与兔抗ＡＬＶ血清发生反应。     

siRNA分析nm23-H1基因与人慢性髓性白血病的关系

设计并筛选靶向nm23-H1基因的siRNAs序列,探讨nm23-H1基因与人慢性髓性白血病之间的关系。依据siRNA设计原则,设计3条siRNA序列。将不同靶点的siRNA用lipofectamine2000转染人慢性髓性白血病细胞株K562。转染后24h RTPCR检测nm23-H1mRNA水平变化;转染后48h免疫细胞化学法检测nm23-H1蛋白表达。MTT法检测转染后24h、48h和72h有效siRNA对K562细胞生长的影响。3条siRNA中,siNM526能有效地抑制K562细胞nm23-H1基因表达,转染siNM526的K56细胞生长受到抑制。说明下调nm23-H1基因的表达有抑制K562细胞增殖的作用,即降低了K562细胞的恶性程度。nm23-H基因有可能成为白血病治疗潜在的分子靶点。     

骨桥蛋白RGD黏附序列多拷贝短肽的表达、纯化及生物学活性测定

目的:用大肠杆菌表达骨桥蛋白RGD黏附序列6拷贝短肽,经分离纯化后检测其生物学活性.方法:运用基因重组技术,将骨桥蛋白RGD黏附序列的核酸片段首尾相连,与携带GST编码序列的原核表达载体连接构建融合蛋白表达质粒pGEX-3X-RGD.将重组质粒转化宿主菌后,对诱导融合蛋白表达的条件进行优化.表达产物GST-RGD经谷胱甘肽-亲和层析纯化后,分别检测其对骨桥蛋白诱导的血管平滑肌细胞黏附和迁移的影响.结果:所构建的含有6个拷贝短肽的GST-RGD融合蛋白可在大肠杆菌中以包含体的形式进行表达.用十二烷基肌氨酸钠变性溶解包含体及透析复性后,经亲和层析可得到高纯度的GST-RGD(6)融合蛋白.GST-RGD(6)融合蛋白能特异性的抑制骨桥蛋白诱导的血管平滑肌细胞的黏附和迁移.结论:骨桥蛋白RGD黏附序列6拷贝短肽可在大肠杆菌中高效表达,纯化的GST-RGD融合蛋白具有抑制血管平滑肌细胞黏附和迁移的活性.     

rhGM—CSF／LIF融合蛋白基因的克隆及表达

利用基因重组技术,人工构建了一个编码五肽Ｇ－Ｓ－Ｇ－Ｇ－Ｓ的基因接头,将ＧＭ－ＣＳＦ和ＬＩＦ的ｃＤＮＡ相连而构成融合基因,将融合基因载入原核表达载体ｐＢＶ２２０后转化大肠杆菌,经热诱导后进行Ｗｅｓｔｅｒｎ印迹反应鉴定证实获得ｒｈＧＭ－ＣＳＦ／ＬＩＦ融合蛋白（简称ｒｈｇＭ－ＬＩＦ）活性测定表明重组的融合蛋白具有两因子双重活性。     

白血病抑制因子受体细胞内区对HL-60细胞表达CD14和CD15的影响

观察白血病抑制因子 (LIF)受体gp190亚基完整的细胞内区和gp190胞内区C末端片段(190CT)对人白血病系HL 6 0表达CD14、CD15的影响 ,进一步了解LIF引发白血病细胞增殖抑制和分化的关系 .用基因重组技术将LIF另一亚基gp130的细胞内区换成gp190的细胞内区 ,用PCR技术扩增gp190细胞内区C末端的一个多肽的编码序列 ,构成嵌合体受体基因 130 /190及 190CT片段 ,并分别在HL 6 0细胞表达 .用免疫组化和流式细胞术检测分析在LIF的诱导下 ,HL 6 0细胞表达CD14、CD15的水平 .转染pcDNA130 /190的HL 6 0细胞 ,CD15表达量明显增高 ;转染pcDNA190CT的细胞 ,CD15的表达量降低 ;但 2组细胞的CD14表达量均较低且水平接近 .LIF可能诱导HL 6 0细胞向粒细胞而不向单核细胞分化 ,该效应是由gp190亚基细胞内区介导的 ,而gp190C末端片段可干扰LIFα受体介导的信号传导效应 .     

Molecular cloning of rat leukemia inhibitory factor receptor α-chain gene and its expression during pregnancy

Leukemia inhibitory factor (LIF) is a secreted glycoprotein and a pluripotent growth factor that acts on diverse cell systems. LIF transmits its effects via binding to transmembrane receptors, of which both high- and low-affinity forms have been identified. In this study, we analyzed the structure and expression of rat LIF receptor α-chain (rLIFRα) cDNA. A full-length clone of the cDNA encoding the membrane-bound form of rLIFRα protein was prepared by a combination of LA-PCR and 5′ RACE using DNA reverse-transcribed from total RNA isolated from the livers of day-12 and day-14 pregnant rats as templates. The nucleotide sequence of a full-length clone was determined and further confirmed by analysis of shorter DNA fragment prepared by PCR using pfu polymerase. The gene for rLIFRα encodes a 1093 amino acid residue protein. The rLIFRα protein shows a high degree of similarity to mouse and human LIF receptor α-chain protein (89% and 76% amino acid sequence identities, respectively). Only one molecular species of mRNA for the rLIFRα gene was detected in the liver and placenta. rLIFRα was expressed in liver of both non-pregnant and pregnant rats. The level of mRNA for the rLIFRα gene in placenta was maximum on day 16 of pregnancy.     

Cloning of leukemia inhibitory factor (LIF) and its expression in the uterus during embryonic diapause and implantation in the mink (Mustela vison)

Leukemia inhibitory factor (LIF) is essential for embryo implantation in mice. Whether LIF plays a role in termination of embryonic diapause and initiation of implantation in carnivores, especially in species with obligate delayed implantation such as the mink, is not known. The objectives of this study were to clone the LIF coding sequence in the mink and determine its mRNA abundance in the uterus through embryonic diapause, implantation, and early postimplantation. We show that the mink LIF cDNA contains 609 nt encoding a deduced protein of 203 amino acids. The homologies are 80.6, 90, 88.2, 87.6, and 86.8% in coding sequence and 79.2, 90.1, 91, 90.1 and 85.4% in amino acid sequence with mouse, human, pig, cow, and sheep respectively. Glycosylation sites and disulfide bonds present in other species are generally conserved in the mink LIF sequence. Quantitation by polymerase chain reaction amplification indicates that LIF mRNA is expressed in mink uterus just prior to implantation and during the first two days after implantation, but not during diapause or later after implantation pregnancy. The abundance of LIF mRNA was significantly higher in the uterus at the embryo expansion stage (P < 0.05) than at days 1–2 of postimplantation. By immunohistochemical localization it was shown that LIF is expressed in the uterine epithelial glands at time of embryonic expansion and in early postimplantation. The coincidence of LIF expression with implantation in this species suggests that LIF is involved in the implantation process, and may be a maternal signal which terminates obligate embryonic diapause. Mol. Reprod. Dev. 51:13–21, 1998. © 1998 Wiley-Liss, Inc.     

Chicken leukemia inhibitory factor maintains chicken embryonic stem cells in the undifferentiated state

Mouse embryonic stem (ES) cells can be maintained in an undifferentiated state in the presence of leukemia inhibitory factor (LIF), a member of the interleukin-6 cytokine family. In other mammals, this is not possible with LIF alone. Chicken ES-like cells (blastodermal cells) have only been cultured with mouse LIF because chicken LIF was not available. However the culture system is imperfect and chicken ES-like cells equivalent to mouse ES cells were not observed. In the present study, we cloned the cDNA-encoding chicken LIF using mRNA subtraction and RACE methodology. The chicken LIF cDNA encodes a protein with approximately 40% sequence identity to mouse LIF. It has 211 amino acids including a putative N-terminal signal peptide of 24 residues. Chicken blastodermal cells were cultured in the presence of bacterially expressed chicken LIF or mouse LIF. The expression of alkaline phosphatase and embryonal carcinoma cell monoclonal antibody-1 and stage-specific embryonic antigen-1 and the activation of STAT3 were examined, all of which are indices of the undifferentiated state. Exposure in the blastodermal cells to recombinant chicken LIF but not to mouse LIF maintained the expression of these various markers. After 9 days of incubation, the blastodermal cells formed cystic embryoid bodies in the presence of mouse LIF but not in the presence of recombinant chicken LIF. We conclude that chicken LIF is able to maintain chicken ES cell cultures in the undifferentiated state.